Relay Therapeutics (RLAY) Total Non-Current Liabilities (2020 - 2024)

Relay Therapeutics (RLAY) has 5 years of Total Non-Current Liabilities data on file, last reported at $93.5 million in Q4 2024.

• On a quarterly basis, Total Non-Current Liabilities rose 18.7% year-over-year to $93.5 million in Q4 2024; TTM through Dec 2024 was $93.5 million, a 18.7% increase from a year earlier, with the FY2024 full-year figure at $93.5 million, up 18.7% from the prior year.
• Total Non-Current Liabilities for Q4 2024 stood at $93.5 million, up from $90.8 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for RLAY reached as high as $126.0 million in Q3 2022 and fell as low as $36.5 million in Q4 2020.
• Historically, Total Non-Current Liabilities has averaged $83.8 million across 5 years, with a median of $84.3 million in 2024.
• Across the five-year window, Total Non-Current Liabilities jumped 151.74% in 2022 and slumped 32.77% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $36.5 million in 2020, then soared by 65.25% to $60.4 million in 2021, then soared by 94.07% to $117.2 million in 2022, then slumped by 32.77% to $78.8 million in 2023, then gained by 18.7% to $93.5 million in 2024.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $93.5 million in Q4 2024, $90.8 million in Q2 2024, and $84.3 million in Q1 2024.